- Home
- XPL vs TNXP Comparison
XPL vs TNXP Comparison
Compare XPL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPL
- TNXP
- Stock Information
- Founded
- XPL 1984
- TNXP 2007
- Country
- XPL United States
- TNXP United States
- Employees
- XPL N/A
- TNXP N/A
- Industry
- XPL Precious Metals
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- XPL Basic Materials
- TNXP Health Care
- Exchange
- XPL Nasdaq
- TNXP Nasdaq
- Market Cap
- XPL 49.4M
- TNXP 57.9M
- IPO Year
- XPL N/A
- TNXP N/A
- Fundamental
- Price
- XPL $0.65
- TNXP $0.24
- Analyst Decision
- XPL Strong Buy
- TNXP Strong Buy
- Analyst Count
- XPL 2
- TNXP 2
- Target Price
- XPL $1.60
- TNXP $53.50
- AVG Volume (30 Days)
- XPL 43.4K
- TNXP 134.8M
- Earning Date
- XPL 11-05-2024
- TNXP 11-12-2024
- Dividend Yield
- XPL N/A
- TNXP N/A
- EPS Growth
- XPL N/A
- TNXP N/A
- EPS
- XPL N/A
- TNXP N/A
- Revenue
- XPL N/A
- TNXP $11,291,000.00
- Revenue This Year
- XPL N/A
- TNXP $64.71
- Revenue Next Year
- XPL N/A
- TNXP $24.49
- P/E Ratio
- XPL N/A
- TNXP N/A
- Revenue Growth
- XPL N/A
- TNXP 183.05
- 52 Week Low
- XPL $0.43
- TNXP $0.12
- 52 Week High
- XPL $0.98
- TNXP $12.48
- Technical
- Relative Strength Index (RSI)
- XPL 58.24
- TNXP 43.95
- Support Level
- XPL $0.59
- TNXP $0.22
- Resistance Level
- XPL $0.63
- TNXP $0.26
- Average True Range (ATR)
- XPL 0.03
- TNXP 0.04
- MACD
- XPL 0.01
- TNXP -0.02
- Stochastic Oscillator
- XPL 78.00
- TNXP 7.38
About XPL Solitario Resources Corp.
Solitario Resources Corp is exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. It has joint venture interests in large, high-grade zinc development projects. The Florida Canyon Zinc Project in Peru is a development asset held jointly with Nexa Resources S.A., Golden Crest Project in South Dakota and the Lik Zinc Project represents a large-tonnage, high-grade development project in Alaska in partnership with Teck Resources. In addition, the company has an additional portfolio of exploration properties and royalties in the Americas.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.